PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 24, 2025Aesthetic Plastic Surgery0 citationsOpen Access

A Multicenter, Randomized, Evaluator-Blind, No-Treatment Controlled Study of YVOIRE Y-Solution 720: A Volumizing Hyaluronic Acid Filler for Midface Volume Deficit

View Full Paper
NYNanze YuWTWenyun TingJXJinhua Xu

Key Points

  • YVOIRE Y-Solution 720 significantly improved midface volume in participants, achieving 82.0% with ≥1-grade reduction at week 26.
  • Only 5.1% of control participants showed similar improvement, showcasing a 77.0% difference, implying YYS720's effectiveness.
  • This randomized controlled study involved 238 Asian participants, assessing volume changes at multiple time points, ensuring robust evaluation.
  • No specific safety concerns were detected, and mild site responses aligned with expected outcomes in filler treatments.

Abstract

Abstract Background Midface volume deficiency is a common aesthetic concern that can be addressed with dermal fillers. YVOIRE Y-Solution 720 (YYS720) is a hyaluronic acid (HA)-based filler designed for midface augmentation. This study aimed to evaluate the effectiveness and safety of YYS720 in improving midface volume. Methods Asian participants with mild to severe midface volume loss were randomly assigned to receive either YYS720 injection (n = 173) or no treatment (control, n = 65). Midface volume was evaluated at 4, 14, and 26 weeks using Midface Volume Deficit Severity Rating Scale for Asian Faces (MFVDA-SRS) for both YYS720 and control groups. Additionally, for YYS720, midface volume was evaluated 52 weeks after the last injection. Results At Week 26, the proportion of participants with ≥ 1-grade reduction on the MFVDA-SRS score was 82.0% (137/167 participants) for YYS720 and 5.1% (3/59 participants) for control with difference (95% confidence interval, CI) between the groups of 77.0% (66.8, 84.0), demonstrating the statistically significant improvement of YYS7720 in midface augmentation. At Week 52, the proportion of participants with ≥1-grade reduction on the MFVDA-SRS score was 76.2% for YYS720 group. Global Aesthetic Improvement Scale (GAIS) responder rates by participants were consistently high in YYS720 group across all time points up to Week 26. No specific safety concern was detected. Common treatment site responses included swelling, tenderness, and pain, which were generally mild and transient. Conclusions This study supports that YVOIRE Y-Solution 720 is an effective and safe option for midface volume augmentation. Level of Evidence I This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yu et al. (2025) studied this question.

synapsesocial.com/papers/68d6d82e8b2b6861e4c3e1b4https://doi.org/10.1007/s00266-025-05246-4
Ask AI
Helpful
Bookmark
Share
View Full Paper